NSE · NIDAN · Healthcare
Nidan Laboratories & Healthcare Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹27 Cr with net profit ₹2 Cr — a 7.38% net margin, versus -12.01% the period before.
Shareholding
As of 2026-06-30
- Promoter57.04%
- Public42.96%
2,359 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.17× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Healthcare · ranked #51 of 79 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Apollo Hospitals Enter. Limited | ₹1,28,472 Cr | 242.67 | 13.55 | 20.48% | 7.7% |
| Max Healthcare Institute Ltd. | ₹1,08,166 Cr | 315.74 | 10.07 | 13.42% | 17.23% |
| Fortis Healthcare Ltd. | ₹71,876 Cr | 270.47 | 7.26 | 10.53% | 11.41% |
| Narayana Hrudayalaya Ltd. | ₹42,315 Cr | 187.89 | 9.34 | 17.76% | 10.2% |
| Aster DM Healthcare Ltd. | ₹42,227 Cr | 299.63 | 9.23 | 8.48% | 8.36% |
| Global Health Limited | ₹38,526 Cr | 267.33 | 9.72 | 14.05% | 12.62% |
| Krishna Institute of Medical Sciences Ltd. | ₹33,517 Cr | 135.03 | 8.94 | 10.74% | 6.18% |
| Dr. Lal Path Labs Ltd. | ₹31,558 Cr | 239.5 | 12.58 | 20.13% | 18.27% |
| Poly Medicure Ltd. | ₹17,015 Cr | 256.67 | 5.47 | 10.37% | 17.18% |
| Dr. Agarwal's Health Care Limited | ₹15,494 Cr | 391.04 | 7.65 | 6.58% | 6.4% |
| Nidan Laboratories & Healthcare Ltd.(this company) | ₹18 Cr | 7.23 | 0.26 | 2.51% | 0% |
AI analysis
AI-generated · google/gemini-2.5-flashNidan Laboratories & Healthcare Ltd. is listed on the Indian markets with a market capitalization of Rs 18 Cr. The company reported revenue of Rs 26.78 Cr and a negative profit margin of 0%. The earnings per share (EPS) for the latest period was Rs 1.26.
Positives
- +The debt-to-equity ratio of 0.18 indicates low financial leverage.
- +The return on equity (ROE) is 251.5%, which is a high return figure.
- +Promoter holding of 57.0388% indicates significant insider ownership and no shares are pledged.
Negatives
- −The profit margin is 0%, indicating no profit generation.
- −Revenue declined from Rs 27.5952 Cr in Mar 2023 to Rs 26.7781 Cr in Mar 2025.
- −Promoter holding decreased from 71.2187% in Mar 2023 to 57.0388% in Mar 2026.
- −The company has not disclosed quarterly results since September 2021 as per the provided data.
Financial performance
The company's revenue declined to Rs 26.7781 Cr in Mar 2025 from Rs 26.9238 Cr in Mar 2024. Net profit improved to Rs 1.9769 Cr in Mar 2025 after a loss of Rs -3.2324 Cr in Mar 2024. Earnings per share (EPS) also recovered to Rs 1.42 in Mar 2025 from Rs -2.33 in Mar 2024.
Profitability & returns
Nidan Laboratories & Healthcare Ltd. reported a return on equity (ROE) of 251.5% and a return on capital employed (ROCE) of 5.9323%. The company's profit margin stood at 0% for the latest period. The standalone EPS for the latest period was Rs 1.26.
Balance sheet
The company's debt-to-equity ratio is 0.18, indicating a relatively low reliance on debt financing. The book value per share is Rs 50.14.
Ownership & pledges
Public shareholding is 42.9612%. There are no shares pledged by the promoters.
Data as of — price: 2026-07-30 · financials: Mar 25 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Nidan Laboratories & Healthcare Ltd.share price & fundamentals